Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312100 | 0.74 | GABRA1 (0.40) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL20825100 | 0.71 | ALDH1A1 (0.46) | LMNACYP1A2CYP3A4HPGDTSHR | |
| SCHEMBL30381967 | 0.69 | GABRA1 (0.57) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL4657600 | 0.69 | GABRA1 (0.57) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL2491376 | 0.68 | GABRA1 (0.35) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL5541323 | 0.67 | GABRA1 (0.40) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL5546613 | 0.65 | GABRA1 (0.39) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL20719348 | 0.61 | GABRA1 (0.39) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL66681 | 0.61 | ALDH1A1 (0.60) | GABRA1LMNAGABRG2GABRB3GABRB2 | |
| SCHEMBL11745542 | 0.61 | GABRA1 (0.48) | GABRA1LMNAGABRG2GABRB3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627689-B1 | SYNTHETIC PROCESSING OILS FOR POLYURETHANE FILLINGS | TUDAPETROL MINERALÖLERZEUGNISSE NILS HANSEN KG (DE) | 2016-12-14 | — | — | EP | claimed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20220204521-A1 | ELECTROACTIVE COMPOUNDS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2022-06-30 | — | — | US | disclosed |
| US-20220140246-A1 | NON-FULLERENE ACCEPTORS (NFAS) AS INTERFACIAL LAYERS IN PEROVSKITE SEMICONDUCTOR DEVICES | CUBIC PEROVSKITE LLC | 2022-05-05 | — | — | US | disclosed |
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| US-20210159419-A1 | NON-FULLERENE ACCEPTORS (NFAS) AS INTERFACIAL LAYERS IN PEROVSKITE SEMICONDUCTOR DEVICES | CUBICPV INC. | 2021-05-27 | — | — | US | disclosed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-10874672-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020231669-A1 | ELECTROACTIVE COMPOUNDS | DUPONT ELECTRONICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-9994555-B2 | Chromenone inhibitors of monocarboxylate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-06-12 | — | — | US | disclosed |
| US-9872911-B2 | Alpha-aminoamidine polymers and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2258356-B1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017157735-A1 | SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-06-29 | — | — | US | disclosed |
| US-9636328-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20160304700-A1 | ORGANIC LAYER COMPOSITION, ORGANIC LAYER, AND METHOD OF FORMING PATTERNS | SAMSUNG SDI CO., LTD. (KR) | 2016-10-20 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2627689-A1 | SYNTHETIC PROCESSING OILS FOR POLYURETHANE FILLINGS | Tudapetrol Mineralölerzeugnisse Nils Hansen KG (DE) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012048874-A1 | SYNTHETIC PROCESSING OILS FOR POLYURETHANE FILLINGS | TUDAPETROL MINERALÖLERZEUGNISSE NILS HANSEN KG (DE) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | GABRA1 656/4885LMNA 2150/4885GABRG2 882/4885 |
| US-20210159419-A1 | NON-FULLERENE ACCEPTORS (NFAS) AS INTERFACIAL LAYERS IN PEROVSKITE SEMICONDUCTOR DEVICES | NBAS, TNK1, NME1 | GABRA1 2632/4885LMNA 1738/4885GABRG2 3214/4885 |
| US-20170182029-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | GABRA1 760/4885LMNA 2533/4885GABRG2 1019/4885 |
| US-20220140246-A1 | NON-FULLERENE ACCEPTORS (NFAS) AS INTERFACIAL LAYERS IN PEROVSKITE SEMICONDUCTOR DEVICES | NBAS, TNK1, NME1 | GABRA1 2632/4885LMNA 1738/4885GABRG2 3214/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | GABRA1 211/4885LMNA 4375/4885GABRG2 123/4885 |
| US-10874672-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | GABRA1 1494/4885LMNA 1284/4885GABRG2 1218/4885 |
| US-20220204521-A1 | ELECTROACTIVE COMPOUNDS | AHR, CYP1B1, KCNH1 | GABRA1 251/4885LMNA 2331/4885GABRG2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.